



SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: MAKING CONNECTIONS, ELEVATING CARE

References:

- Adegunsoye A, Oldham JM, Husain AN, et al. Autoimmune Hypothyroidism As a Predictor of Mortality in Chronic Hypersensitivity Pneumonitis. *Front Med (Lausanne)*. 2017;4:170. doi: 10.3389/fmed.2017.00170.
- Barsotti S, Orlandi M, Codullo V, et al. One year in review 2019: systemic sclerosis. *Clin Exp Rheumatol*. 2019;37 Suppl 119:3-14.
- Bernstein EJ, Jaafar S, Assassi S, et al. Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. *Arthritis Rheumatol*. 2020;72(11):1892-1896. doi: 10.1002/art.41415. Erratum in: *Arthritis Rheumatol*. 2021;73(4):720.
- Chowaniek M, Skoczyńska M, Sokolik R, Wiland P. Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management. *Reumatologia*. 2018;56(4):249-254. doi: 10.5114/reum.2018.77977.
- Clarke J. European consensus reached on interstitial lung disease in SSc. *Nat Rev Rheumatol*. 2020;16(3):127. doi: 10.1038/s41584-020-0379-3.
- ClinicalTrials.gov. Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate (SLSIII). Last updated November 17, 2021. Available at <https://clinicaltrials.gov/ct2/show/NCT03221257>.
- Cutolo M, Soldano S, Smith V. Pathophysiology of systemic sclerosis: current understanding and new insights. *Expert Rev Clin Immunol*. 2019;15(7):753-764. doi: 10.1080/1744666X.2019.1614915.
- Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. *Rheumatology (Oxford)*. 2010;49(2):271-80. doi: 10.1093/rheumatology/kep093.
- DeMizio DJ, Bernstein EJ. Detection and classification of systemic sclerosis-related interstitial lung disease: a review. *Curr Opin Rheumatol*. 2019;31:553-560.
- Distler O, Assassi S, Cottin V, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. *Eur Respir J*. 2020;55:1-12.
- Distler O, Highland KB, Gahlemann M, et al; SENSICIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. *N Engl J Med*. 2019;380(26):2518-2528. doi: 10.1056/NEJMoa1903076.
- Distler O, Volkman ER, Hoffmann-Vold AM, Maher TM. Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. *Expert Rev Clin Immunol*. 2019;15(10):1009-1017. doi: 10.1080/1744666X.2020.1668269.
- Fan Y, Bender S, Shi W, Zoz D. Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States. *J Manag Care Spec Pharm*. 2020;26(12):1539-1547. doi: 10.18553/jmcp.2020.20136.
- Fischer A, Patel NM, Volkman ER. Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention. *Open Access Rheumatol*. 2019;11:283-307. doi: 10.2147/OARRR.S226695.



SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: MAKING CONNECTIONS, ELEVATING CARE

Fischer A, Zimovetz E, Ling C, Esser D, Schoof N. Humanistic and cost burden of systemic sclerosis: A review of the literature. *Autoimmun Rev.* 2017;16(11):1147-1154. doi: 10.1016/j.autrev.2017.09.010.

Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. *N Engl J Med.* 2019; 381:1718-1727.

Giacomelli R, Liakouli V, Berardicurti O, et al. Interstitial lung disease in systemic sclerosis: current and future treatment. *Rheumatol Int.* 2017;37:853-863.

Herrick AL. Raynaud's phenomenon. *J Scleroderma Relat Disord.* 2019;4:89-101.

Highland KB, Distler O, Kuwana M, et al; SENSICIS trial investigators. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSICIS trial. *Lancet Respir Med.* 2021;9(1):96-106. doi: 10.1016/S2213-2600(20)30330-1.

Hoffmann-Vold AM, Molberg Ø. Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis. *Curr Opin Rheumatol.* 2020;32(6):497-504. doi: 10.1097/BOR.0000000000000741.

Jaeger VK, Wirz EG, Allanore Y, et al; EUSTAR co-authors. Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. *PLoS One.* 2016;11(10):e0163894. doi: 10.1371/journal.pone.0163894.

Khanna D, Lin CJF, Furst DE, et al; focuSSced investigators. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med.* 2020;8(10):963-974. doi: 10.1016/S2213-2600(20)30318-0. Erratum in: *Lancet Respir Med.* 2020;8(10):e75. Erratum in: *Lancet Respir Med.* 2021;9(3):e29.

Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. *Am J Respir Crit Care Med.* 2020;201(6):650-660. doi: 10.1164/rccm.201903-0563CI.

Kowal-Bielecka O, Franssen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis.* 2017;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909.

Kuwana M, Azuma A. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease. *Mod Rheumatol.* 2020;30(2):225-231. doi: 10.1080/14397595.2019.1696505. Erratum in: *Mod Rheumatol.* 2019.

Li Q, Wallace L, Patnaik P, et al. Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study. *Rheumatology (Oxford).* 2021;60(4):1915-1925. doi: 10.1093/rheumatology/keaa547.

Lin Y-T, Chuang Y-S, Wang J-W, Wu P-H. High risk of gastrointestinal hemorrhage in patients with systemic sclerosis. *Arthritis Res Ther.* 2019;21:301.

Luquez-Mindiola A, Atuesta AJ, Gómez-Aldana AJ. Gastrointestinal manifestations of systemic sclerosis: An updated review. *World J Clin Cases.* 2021;9(22):6201-6217. doi: 10.12998/wjcc.v9.i22.6201.



SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: MAKING CONNECTIONS, ELEVATING CARE

- McMahan ZH, Volkman ER. An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis. *Expert Opin Pharmacother*. 2020;21(16):2041-2056. doi: 10.1080/14656566.2020.1793960.
- Pellar RE, Pope JE. Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines. *Semin Arthritis Rheum*. 2017;46(6):767-774. doi: 10.1016/j.semarthrit.2016.12.003.
- Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. *Lancet Respir Med*. 2020;8(3):304-320. doi: 10.1016/S2213-2600(19)30480-1.
- Roofeh D, Khanna D. Management of systemic sclerosis: the first five years. *Curr Opin Rheumatol*. 2020;32(3):228-237. doi: 10.1097/BOR.0000000000000711.
- Silver RM, Bogatkevich G, Tourkina E, Nietert PJ, Hoffman S. Racial differences between blacks and whites with systemic sclerosis. *Curr Opin Rheumatol*. 2012;24(6):642-8. doi: 10.1097/BOR.0b013e328356d9dc.
- Sircar G, Goswami RP, Sircar D, et al. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. *Rheumatology (Oxford)*. 2018;57:2106-2113.
- Sullivan KM, et al; SCOT Study Investigators. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. *N Engl J Med*. 2018;378(1):35-47. doi: 10.1056/nejmoa1703327.
- Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. *N Engl J Med*. 2006;354(25):2655-66. doi: 10.1056/NEJMoa055120.
- Tashkin DP, Roth MD, Clements PJ, et al; Scleroderma Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. *Lancet Respir Med*. 2016;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7.
- van Laar JM, et al; EBMT/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. *JAMA*. 2014;311(24):2490-8. doi: 10.1001/jama.2014.6368.
- Volkman ER, Fischer A. Update on Morbidity and Mortality in Systemic Sclerosis-Related Interstitial Lung Disease. *J Scleroderma Relat Disord*. 2021;6(1):11-20. doi:10.1177/2397198320915042
- Volkman ER, Tashkin DP, LeClair H, et al. Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II. *ACR Open Rheumatol*. 2020;2(6):362-370. doi: 10.1002/acr2.11125.
- Volkman ER, Tashkin DP. Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies. *Ann Am Thorac Soc*. 2016;13(11):2045-2056. doi: 10.1513/AnnalsATS.201606-426FR.
- Zhang XJ, Bonner A, Hudson M, Canadian Scleroderma Research Group; Baron M, Pope J. Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis. *J Rheumatol*. 2013;40:850-858.